Renaming Sjögren’s syndrome as Sjögren’s disease is meant to better reflect that it’s a serious autoimmune disease, not just a collection of symptoms, and to offer some clarity across clinical and research settings. An international group of doctors and patients agreed to the name change in 2023 through a…
Read more
Telitacicept safely and effectively eased disease activity in adults with primary Sjögren’s disease, according to data from a now-complete Phase 3 clinical trial conducted in China. Because the trial met its primary goal, developer Remegen plans to ask China’s regulator, the Center for Drug Evaluation of the National Medical…
Novartis’ investigational antibody therapy ianalumab (VAY736) safely and effectively eases disease activity in adults with Sjögren’s disease, topline results from a pair of Phase 3 clinical trials show. According to the therapy’s developer, ianalumab has the potential to become the first targeted treatment to be approved for people…
Levels of the receptor protein Mer tyrosine kinase (MerTK) in small salivary glands may be a useful marker for tracking disease activity and estimating tissue damage in Sjögren’s disease, a study reports. Researchers found that elevated MerTK, which plays a role in immune inflammation, was significantly associated with more…
Get regular updates to your inbox.
